drugset / Trial / NCT00549133

Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol

NCT00549133

Phase 4 Completed 44 enrolled Sanofi
RandomizedSingle-groupOpen-labelTreatment

Summary

To show that Irbesartan improves endothelial dysfunction and the procoagulant state which are thought to be the possible mechanisms, inducing a generalized vasculopathy associated with microalbuminuria and vascular events in type II diabetic hypertensive patients

Timeline

Start
2003-10
Primary completion
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Irbesartan Small molecule